Simona Maria Ceccarelli

USPTO Granted Patents = 42 (Patent Applications = 4)

CIPO Patents = 3 (Patent Applications = 8)

EPO Patents = 22 (Patent Applications = 17)

Average Co-Inventor Count = 5.2

ph-index = 6

Forward Citations = 120(Granted Patents)

Company Filing History:

41 out of 4,942

Hoffmann-la Roche Inc.

Years Active: 2006-2017

Loading Chart...

42 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9809599 - Aryl-quinoline derivatives (2017-11-07),

2. 9708340 - Urea derivatives and their use as fatty-acid binding protein (FABP) inhibitors (2017-07-18),

3. 9688675 - 1,7-naphthyridine derivatives (2017-06-27),

4. 9657014 - Substituted 1,6-naphthyridines (2017-05-23),

5. 9604977 - Bicyclic thiophenylamide compounds (2017-03-28),

6. 9586903 - Isoquinoline derivatives (2017-03-07),

7. 9440962 - Benzisoxazoles (2016-09-13),

8. 9365550 - Benzimidazoles as CNS active agents (2016-06-14),

9. 9353102 - Non-annulated thiophenylamides (2016-05-31),

10. 9315502 - Imidazopyridine derivatives (2016-04-19),

11. 9284321 - Piperazino[1,2-a]indol-1-ones and [1,4]diazepino[1,2-a]indol-1-one (2016-03-15),

12. 9278918 - Urea derivatives and their use as fatty-acid binding protein (FABP) inhibitors (2016-03-08),

13. 9199938 - Aryl-quinoline derivatives (2015-12-01),

14. 9139593 - Azetidine compounds, compositions and methods of use (2015-09-22),

15. 8809552 - Azetidine compounds, compositions and methods of use (2014-08-19),

Title: Innovations of Simona Maria Ceccarelli in Basel, CH

Introduction

Simona Maria Ceccarelli is a prominent inventor based in Basel, Switzerland. With an impressive portfolio of 42 patents, she has made significant contributions to the field of pharmaceuticals and biotechnology.

Latest Patents

Among her latest inventions are aryl-quinoline derivatives, offering novel compounds useful as fatty-acid binding protein (FABP) 4 and/or 5 inhibitors. These compounds show promise in treating various conditions such as lipodystrophy, type 2 diabetes, dyslipidemia, atherosclerosis, and liver diseases linked to inflammation and fibrosis, including non-alcoholic fatty liver disease. Furthermore, she has developed urea derivatives, similarly serving as inhibitors for FABP, which have wide potential applications in the medical field.

Career Highlights

Ceccarelli honed her skills and expertise while working with renowned companies such as Hoffmann-La Roche Inc. and Roche Palo Alto LLC. Her innovative approaches have consistently contributed to advancements in therapeutic treatments.

Collaborations

Through her career, Simona has collaborated with esteemed colleagues, including Bernd Buettelmann and Odile Chomienne. These partnerships have played a vital role in enhancing her research and fostering innovation.

Conclusion

Simona Maria Ceccarelli continues to push the boundaries of scientific discovery with her invaluable inventions. Her contributions not only showcase her ingenuity but also hold the potential to significantly impact healthcare and improve the lives of individuals suffering from various medical conditions.

This text is generated by artificial intelligence and may not be accurate.